Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $69M (up 25.6% year over year) with net income of $28M.
Q3 2025 key financials · XBRL
- Revenue
- $69M
- +25.6% YoY · −31.7% QoQ
- Net income
- $28M
- +124.6% YoY · −53.2% QoQ
- Operating margin
- 40.9%
- EPS (diluted)
- $1.47
- +107.0% YoY · −55.2% QoQ
Source: XBRL data from the RIGEL PHARMACEUTICALS INC (RIGL) Q3 2025 10-Q on SEC EDGAR. USD.
RIGEL PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Nine-month product sales $166.6M, up from $97.4M YoY
- Best performer TAVALISSE sales $113.3M, up 54% YoY
- REZLIDHIA sales $21.4M, up 38% YoY
- GAVRETO sales $31.9M vs $9.0M YoY
- R289 headwind: one reported responder reclassified as non-responder after July 15, 2025 data review
Risk Factors
- Newly substantive manufacturing risk: reliance on third parties for clinical and commercial supply, manufacturing, and distribution
- Clinical-development risk: R289 responder reclassified as non-responder after July 15, 2025 data-cut review found uncaptured transfusions
- Regulatory compliance risk: EU Clinical Trials Regulation applies to all ongoing EU trials from January 31, 2025
- Product-safety risk: GAVRETO safety signal prompted October 2024 Dear Healthcare Provider Letter and enhanced infection monitoring
- Commercial risk: GAVRETO market opportunity exposed to competition from generic versions of company products
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RIGEL PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.